JANX Logo

Janux Therapeutics, Inc. (JANX) 

NASDAQ$29.69+5.31 (21.78%)
Market Cap
$1.44B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
3 of 893
Rank in Industry
2 of 513

JANX Insider Trading Activity

JANX Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$79,042,965
4
14
Sells
$342,728,126
25
86

Related Transactions

RA CAPITAL MANAGEMENT, L.P.
4
$79.04M
0
$0
$79.04M
DiRaimondo ThomasChief Scientific Officer
0
$0
1
$231,716
$-231,716
Meyer Andrew HollmanChief Business Officer
0
$0
4
$3.28M
$-3.28M
Campbell David AlanPresident and CEO
0
$0
6
$6.5M
$-6.5M
Reardon TigheActing Chief Financial Officer
0
$0
1
$45.04M
$-45.04M
Lichter Jay
0
$0
2
$82.3M
$-82.3M
Avalon Ventures XI, L.P.10 percent owner
0
$0
11
$205.38M
$-205.38M

About Janux Therapeutics, Inc.

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against â€¦

Insider Activity of Janux Therapeutics, Inc.

Over the last 12 months, insiders at Janux Therapeutics, Inc. have bought $79.04M and sold $342.73M worth of Janux Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Janux Therapeutics, Inc. have bought $69.09M and sold $181.95M worth of stock each year.

Highest buying activity among insiders over the last 12 months: RA CAPITAL MANAGEMENT, L.P. () — $79.04M.

The last purchase of 110,206 shares for transaction amount of $3.42M was made by RA CAPITAL MANAGEMENT, L.P. () on 2025‑03‑07.

List of Insider Buy and Sell Transactions, Janux Therapeutics, Inc.

2025-03-07PurchaseRA CAPITAL MANAGEMENT, L.P.
110,206
0.187%
$31.02
$3.42M
-1.38%
2025-03-06PurchaseRA CAPITAL MANAGEMENT, L.P.
372,093
0.6366%
$30.78
$11.45M
-1.94%
2025-03-05PurchaseRA CAPITAL MANAGEMENT, L.P.
341,742
0.5742%
$30.64
$10.47M
-4.16%
2025-03-03SaleMeyer Andrew HollmanChief Business Officer
3,334
0.0059%
$32.15
$107,174
-5.15%
2025-02-03SaleMeyer Andrew HollmanChief Business Officer
3,334
0.0056%
$42.29
$140,999
-25.11%
2025-01-07SaleCampbell David AlanPresident and CEO
5,000
0.009%
$60.00
$300,004
-41.91%
2025-01-02SaleMeyer Andrew HollmanChief Business Officer
13,334
0.0234%
$54.88
$731,785
-32.21%
2024-12-24SaleCampbell David AlanPresident and CEO
25,000
0.0433%
$56.19
$1.4M
-34.20%
2024-12-03SaleCampbell David AlanPresident and CEO
15,000
0.0317%
$67.00
$1M
-32.52%
2024-11-25SaleCampbell David AlanPresident and CEO
25,000
0.0505%
$51.60
$1.29M
-16.67%
2024-10-28SaleCampbell David AlanPresident and CEO
25,000
0.0486%
$53.54
$1.34M
-18.86%
2024-10-18SaleAvalon Ventures XI, L.P.10 percent owner
1.46M
2.5633%
$45.76
$66.9M
-10.47%
2024-10-18PurchaseRA CAPITAL MANAGEMENT, L.P.
1.2M
2.0576%
$44.75
$53.7M
-10.47%
2024-10-17SaleAvalon Ventures XI, L.P.10 percent owner
1,843
0.0035%
$50.02
$92,187
-9.81%
2024-10-16SaleAvalon Ventures XI, L.P.10 percent owner
209,516
0.4311%
$50.03
$10.48M
-8.80%
2024-09-30SaleAvalon Ventures XI, L.P.10 percent owner
958
0.0018%
$46.24
$44,298
-0.81%
2024-09-27SaleCampbell David AlanPresident and CEO
25,000
0.0476%
$46.31
$1.16M
-2.41%
2024-09-27SaleDiRaimondo ThomasChief Scientific Officer
5,000
0.0095%
$46.34
$231,716
-2.41%
2024-09-27SaleMeyer Andrew HollmanChief Business Officer
50,000
0.0945%
$45.96
$2.3M
-2.41%
2024-09-27SaleAvalon Ventures XI, L.P.10 percent owner
106,821
0.2041%
$46.46
$4.96M
-2.41%
Total: 46
*Gray background shows transactions not older than one year

Insider Historical Profitability

134.4%
RA CAPITAL MANAGEMENT, L.P.
10141287
17.158%
$247.24M60
<0.0001%
Reardon TigheActing Chief Financial Officer
633673
1.0721%
$15.45M21
+247.14%
Avalon Ventures XI, L.P.10 percent owner
401321
0.679%
$9.78M211
+247.14%
Lichter Jay10 percent owner
7000
0.0118%
$170,660.0022
+247.14%
Bregua Corp10 percent owner
3749250
6.3434%
$91.41M10
+1.61%
ORBIMED ADVISORS LLCdirector
231098
0.391%
$5.63M13
+1.61%
Thompson Peter A.director
231098
0.391%
$5.63M13
+1.61%
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$831,902,292
108
9.34%
$1.43B
$20,297,544
73
103.06%
$1.42B
$11,583,737
45
49.75%
$1.35B
$148,770,544
34
80.63%
$1.27B
$150,253,463
26
-52.83%
$1.5B

JANX Institutional Investors: Active Positions

Increased Positions159+116.06%21M+46.04%
Decreased Positions61-44.53%2M-4.41%
New Positions79New6MNew
Sold Out Positions22Sold Out969,051Sold Out
Total Postitions235+71.53%64M+41.63%

JANX Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Ra Capital Management, L.P.$298,531.0017.57%10.37M+1M+13.09%2024-12-31
Fmr Llc$249,694.0014.7%8.67M+845,266+10.8%2024-12-31
Janus Henderson Group Plc$102,597.006.04%3.56M+1M+41.17%2024-12-31
Paradigm Biocapital Advisors Lp$101,260.005.96%3.52M+1M+46.46%2024-12-31
Adage Capital Partners Gp, L.L.C.$88,178.005.19%3.06M+986,750+47.55%2024-12-31
Blackrock, Inc.$78,503.004.62%2.73M+303,177+12.51%2024-12-31
Vanguard Group Inc$61,526.003.62%2.14M+288,402+15.61%2024-12-31
Cormorant Asset Management, Lp$60,480.003.56%2.1M+1MNew2024-12-31
Woodline Partners Lp$53,343.003.14%1.85M+251,924+15.74%2024-12-31
Ecor1 Capital, Llc$42,331.002.49%1.47M00%2024-12-31

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.